Publications

Read ASGCT's 2022 Q4 Landscape Analysis Field Report

January 20, 2023

The Gene, Cell, & RNA Therapy Landscape report from ASGCT and Citeline (formerly Informa Pharma Intelligence) is the only field-wide report covering the therapeutics pipeline, clinical targets, developer progress, and more.

The fourth quarterly report of 2022 from ASGCT and Citeline (formerly Informa Pharma Intelligence) is available now! The Gene, Cell, & RNA Therapy Landscape report is the only field-wide report covering the therapeutics pipeline, clinical targets, developer progress, and more.

Highlights from this issue include:

  • Hemgenix, Adstiladrin approved in the U.S. for hemophilia B and bladder cancer, respectively

  • Ebvallo approved for Epstein-Barr virus-positive post-transplant lymphoproliferative disease

  • Across 2022, the pipeline (preclinical to pre-registration) of gene, cell, and RNA therapies grew by 7%

Download the full report


Click any of the samples below to view the full report: